Tamoxifen therapy and hepatic steatosis

被引:1
作者
Coskun, U [1 ]
Törüner, FB
Günel, N
机构
[1] Gazi Univ, Sch Med, Dept Med Oncol, TR-06500 Ankara, Turkey
[2] Dept Endocrinol & Metab, TR-06500 Ankara, Turkey
关键词
tamoxifen; lipid levels; hepatic steatosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tamoxifen has been used for a long time as a hormonal treatment in breast cancer. Recent studies in pre and postmenopausal women have shown that tamoxifen exhibits favorable effects on the lipid profile. In this study we investigated the effects of tamoxifen on lipid profile and hepatic steatosis. Fifty two (31 postmenopausal and 21 premenopausal) women with breast cancer treated with tamoxifen at a dose of 20 mg daily were included in the study. Serum lipid parameters (total cholesterol, high and low density lipoprotein cholesterol and triglyceride) were measured baseline and at the 6th month of tamoxifen treatment. Upper abdominal ultrasonography was performed before and at the 6th month of therapy for assessment of liver steatosis. We obtained decreased levels of serum total cholesterol after 6 months of tamoxifen treatment (p < 0.05). However, we did not detect any changes in triglyceride and high-density lipoprotein cholesterol levels (p > 0.05). Increased liver steatosis was observed in 22 patients (42.3%) after tamoxifen treatment. We could not detect increase in lipid levels in these patients. There was no significant difference between the lipid levels in the patients with increased liver steatosis and stable or no liver steatosis. Whether hepatic steatosis is dependent on lipid changes in tamoxifen use should be further investigated.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 24 条
  • [1] EFFECTS OF TAMOXIFEN TREATMENT ON PLASMA-LIPIDS AND LIPOPROTEIN LIPID-COMPOSITION
    BAGDADE, JD
    WOLTER, J
    SUBBAIAH, PV
    RYAN, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) : 1132 - 1135
  • [2] TAMOXIFEN, SERUM-LIPOPROTEINS AND CARDIOVASCULAR RISK
    BRUNING, PF
    BONFRER, JMG
    HART, AAM
    DEJONGBAKKER, M
    LINDERS, D
    VANLOON, J
    NOOYEN, WJ
    [J]. BRITISH JOURNAL OF CANCER, 1988, 58 (04) : 497 - 499
  • [3] Cai Q, 2000, AM J GASTROENTEROL, V95, P277
  • [4] Clarke M, 1998, LANCET, V351, P1451
  • [5] LONG-TERM EFFECTS OF TAMOXIFEN ON BLOOD LIPID VALUES IN BREAST-CANCER
    DEWAR, JA
    HOROBIN, JM
    PREECE, PE
    TAVENDALE, R
    TUNSTALLPEDOE, H
    WOOD, RAB
    [J]. BRITISH MEDICAL JOURNAL, 1992, 305 (6847) : 225 - 226
  • [6] Elisaf M, 1996, ANTICANCER RES, V16, P2725
  • [7] A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS
    FISHER, B
    COSTANTINO, J
    REDMOND, C
    POISSON, R
    BOWMAN, D
    COUTURE, J
    DIMITROV, NV
    WOLMARK, N
    WICKERHAM, DL
    FISHER, ER
    MARGOLESE, R
    ROBIDOUX, A
    SHIBATA, H
    TERZ, J
    PATERSON, AHG
    FELDMAN, MI
    FARRAR, W
    EVANS, J
    LICKLEY, HL
    KETNER, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) : 479 - 484
  • [8] THE EFFECT OF THE ANTIESTROGEN TAMOXIFEN ON CARDIOVASCULAR RISK-FACTORS IN NORMAL POSTMENOPAUSAL WOMEN
    GREY, AB
    STAPLETON, JP
    EVANS, MC
    REID, IR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (11) : 3191 - 3195
  • [9] HOFF MV, 1996, ANN INTERN MED, V124, P855
  • [10] Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery
    Hozumi, Y
    Kawano, M
    Miyata, M
    [J]. ENDOCRINE JOURNAL, 1997, 44 (05) : 745 - 749